Yeh, when I read the headline, late breaking interum 202 trial results, than feeds onto efficacy and safety of the 202 study.
Although, given that they are making statements that it inhibits alpha synuclien aggregation and brain mass loss from advanced imaging, they must be pretty confident.
Also given they will need to present an outstanding end readout, im happy if they take a little longer than Jan to reach the goal, as it will be a major market mover.
ATH Price at posting:
0.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)